Table 1.

Suppression of gastric cancers by 5-aza-dC

Adenocarcinoma
GroupEffective numberWell-differentiatedPoorly differentiatedMultiplicity (mean ± SD)Diameter (mean ± SD), mmIncidence (%)AdenomaSarcoma
G1. HP(−) + DW80000/8 (0)00
G2. HP(−) + MNU + PBS29331.0 ± 06.3 ± 1.66/29 (20.7)12
G3. HP(−) + MNU + 5-aza-dC33021.0 ± 03.3 ± 3.32/33 (6.1)10
G4. HP(+) + DW80000/8 (0)00
G5. HP(+) + MNU + PBS291511.1 ± 0.35.7 ± 2.716/29 (55.2)a02
G6. HP(+) + MNU + 5-aza-dC30431.0 ± 04.8 ± 1.77/30 (23.3)b02

NOTE: 5-Aza-dC treatment decreased incidence of gastric cancers (adenocarcinomas) from 55.2% (G5) to 23.3% (G6).

  • aP < 0.05 compared with G3.

  • bP < 0.05 compared with G5.